B
Bull
Bull · 25%STVN
$30.64
Szenariopreis
$21.030
-1.199 (-5.70%)Zum Schluss
Loading chart…
- High
- 22.260
- Open
- 22.230
- VWAP
- 21.38
- Vol
- 344.07K
- Mkt Cap
- 5.11B
- Low
- 20.860
- Amount
- 7.36M
- EV/EBITDA, TTM
- 19.39
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
AI analysis of Stevanato Group SpA (STVN)
buyStevanato Group (STVN) is a good buy right now due to its current price of $21.03 being significantly lower than the analyst price target of $25 from TD Cowen, indicating a potential upside of approximately 19%. Additionally, the forward P/E ratio of 7.22 suggests the stock is undervalued relative to its earnings potential. However, a risk to consider is the recent decline in net income, which dropped to €22.96 million in Q2 2026, down from €28.03 million in Q1 2026, reflecting a potential concern in profitability.
Bewertungskennzahlen
The current forward P/E ratio for Stevanato Group SpA (STVN) is 7.22, compared to its 5-year average forward P/E of 36.18.
Alphio AI Price Scenarios for STVN
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding STVN
Event-Zeitleiste
News
2.008-05NASDAQ.COMStevanato (STVN) Q2 2026 Earnings Call Transcript
9.508-04seekingalphaStevanato Group Reports Strong Q2 Earnings with Strategic Divestiture
8.508-04NewsfilterStevanato Group Divests California Subsidiary Balda C. Brewer, Inc.
- 8.507-30Newsfilter
Stevanato Group Secures European Approvals for New Injector Therapies
- 9.507-21Newsfilter
Stevanato Group to Release Q2 2026 Financial Results
STVN FAQ — answered by Alphio AI
Stevanato Group SpA is an Italy-based manufacturer and distributor engaged in two segments: Biopharmaceutical and Diagnostic Solutions and Engineering, including the production and distribution of drug containment solutions, drug delivery systems, and diagnostic solutions in the pharmaceutical industry. The Company delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The Company operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States. It operates in the Healthcare sector (SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS industry).
Stevanato Group (STVN) is a good buy right now due to its current price of $21.03 being significantly lower than the analyst price target of $25 from TD Cowen, indicating a potential upside of approximately 19%. Additionally, the forward P/E ratio of 7.22 suggests the stock is undervalued relative to its earnings potential. However, a risk to consider is the recent decline in net income, which dropped to €22.96 million in Q2 2026, down from €28.03 million in Q1 2026, reflecting a potential concern in profitability.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.